A Human Proof of Concept Study of REC-2282 in Neurofibromatosis Type 2 (NF2)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jan 2019 New trial record
04 Jan 2019 According to a Recursion Pharmaceuticals media release, the company has entered into a licensing agreement with the Ohio State Innovation Foundation (OSIF), the technology transfer function of The Ohio State University, gaining rights to OSU-HDAC42, a clinical-stage compound that will be developed by Recursion as REC-2282.The company is excited to build on existing clinical data to advance REC-2282 to this human proof of concept trial in neurofibromatosis type 2 (NF2) as rapidly as possible.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com